Biologics World Korea: Counting On A Paradigm Shift In Biologics Market
This article was originally published in PharmAsia News
Biopharmaceutical experts from around the world gathered in Seoul at the recent Biologics World Korea 2015, at which a group of panelists discussed the strategic direction of the biologics industry in Asia and a paradigm shift in the global biologics market.
You may also be interested in...
After record venture capital activity around South Korean biotechs last year, the strong investment interest has persisted so far this year, with an increased number of companies receiving large-scale funding as the promising sector emerges amid the pandemic.
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.
Legislation that could thin the crowded generic market clears first parliamentary hurdle as brand and generic firms alike react to the recent generic quality issue raised by recent manufacturing incidences at some South Korean pharma firms.